Biofrontera Inc. filed a Form 8-K on November 20, 2026, disclosing that it received a Nasdaq deficiency notice on November 16, 2026, for failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
Key Highlights
- Deficiency notice received: Biofrontera received a letter from Nasdaq's Listing Qualifications Department on November 16, 2026, citing non-compliance with Nasdaq Listing Rule 5550(a)(2).
- Cause of non-compliance: The closing bid price of the company's common stock was less than $1.00 per share for the previous 30 consecutive business days, according to the filing.
- Compliance deadline: The company has 180 calendar days, or until May 17, 2027, to regain compliance under Nasdaq Listing Rule 5810(c)(3)(A).
- Compliance threshold: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days during the compliance period.
- No immediate trading impact: The filing states the notice "has no present impact on the listing or trading of the Company's securities on The Nasdaq Capital Market."
- Potential appeal path: If compliance is not regained, the company may appeal any delisting determination to a Hearings Panel, the filing notes.
Biofrontera Discloses Nasdaq Minimum Bid Price Non-Compliance
According to the Form 8-K filed with the SEC on November 20, 2026, Biofrontera Inc. (NASDAQ:BFRI) disclosed that it received a formal deficiency notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC. The notice, dated November 16, 2026, stated that the company was not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires that listed securities maintain a minimum closing bid price of $1.00 per share. The company's common stock had closed below that threshold for 30 consecutive business days prior to the notice.
The filing states that the company has until May 17, 2027, a period of 180 calendar days, to cure the deficiency. During that window, the closing bid price of the common stock must reach at least $1.00 per share for a minimum of 10 consecutive business days. The filing also notes that if compliance is not achieved within the initial 180-day period, Biofrontera may be eligible for an additional compliance period, provided it meets continued listing requirements for market value of publicly held shares and all other applicable initial listing standards, with the exception of the minimum bid price requirement, and submits written notice to Nasdaq of its intention to cure the deficiency, which could include effecting a reverse stock split.
The filing states that "the Company intends to actively monitor the closing bid price of its common stock and, as appropriate, will consider available options to resolve the deficiency and regain compliance with the Nasdaq Listing Rules." The company added that "there can be no assurance that the Company will be able to regain compliance with Rule 5550(a)(2) or maintain compliance with the other listing requirements of the Nasdaq Capital Market." The report was signed by E. Fred Leffler III, Chief Financial Officer of Biofrontera Inc.
What Was Disclosed
Biofrontera Inc. disclosed receipt of a Nasdaq bid-price deficiency notice dated November 16, 2026, citing non-compliance with Nasdaq Listing Rule 5550(a)(2). The company has until May 17, 2027, to regain compliance and reported no immediate impact on the trading of its securities.




Please wait processing your request...